ABL1 and acute lymphoblastic leukemia: Strategies for direct modulation of T cells to minimize their excessive inflammatory cytokine production upon target antigen contact have demonstrated promise in preclinical studies, including reversible dampening of normal endogenous T cell (needed for blinatumomab engagement) or CD19CART functionality when exposed in vitro to the SRC/ABL inhibitor dasatinib and protection from CRS in B-ALL models [47, 48].